Protein aggregation and deposition: Implications for ion channel formation and membrane damage

Croatian Medical Journal

Volumn 42, Issue 4, 2001, Pages 359-374

  Kourie, J I ^a   Henry, C U ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Amyloid; Amyloid neuropathies; Amyloid beta protein; Complement 1q; Copper; Glycosaminoglycans; Iron; Peptides; Zinc

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CELL PROTEIN; COMPLEMENT COMPONENT C1Q; GLYCOSAMINOGLYCAN; ION CHANNEL; IRON; METAL; PEPTIDE; ZINC;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; BETA SHEET; CELL MEMBRANE PERMEABILITY; CHANNEL GATING; DEGENERATIVE DISEASE; GENE MUTATION; HOMEOSTASIS; HYDROPHOBICITY; MEMBRANE DAMAGE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN TRANSPORT; REVIEW; SURFACE CHARGE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID NEUROPATHIES; AMYLOIDOSIS; APOLIPOPROTEINS E; CELL AGGREGATION; CELL MEMBRANE; ENDOPLASMIC RETICULUM; HUMANS; ION CHANNELS; MUTATION; PRIONS; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 0034865788     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Channel formation in the pathogenesis of Alzheimer's disease and other Amyloidoses
2. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates
3. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants
4. Formation of insulin amyioid fibrils followed by Fourier transform infrared spectroscopysimultaneously with circular dichroismand electron microscopy
5. Kinetics and mechanism of amyloid formation by the prion protein H1 peptide as determined by time-dependent ESR
6. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy
7. Inclusion body myositis (IBM)
8. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles
9. Alzheimer's disease: Its origin at the membrane, evidence and questions
10. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes
11. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity
12. Specific modulation of the fusogenic properties of the Alzheirner beta-amyloid peptide by apolipoprotein E isoforms
13. Activation effects of prion protein fragment [PrP-(106-126)] on human leucocytes
14. 3 release
15. Signal transduction through prion protein
16. A mutant prion protein displays an aberrant membrane association when expressed in cultured cells
17. Spongiform encephalopathies. Breech-birth prions
18. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein
19. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein
20. Channel formation by a neurotoxic prion protein fragment
21. Channel formation in the pathogenesis of Alzheimer's disease and other amylo-idoses
22. 2+-channel hypothesis for neuronal death in Alzheimer disease
23. 2+ interaction with Alzheimer amyloid β protein calcium channels
24. Giant multilevel cation channels formed by Aizheimer disease amyloid beta-protein [AβP-(1-40)] in bilayer membranes
25. 2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons
26. Alzheimer amyloid Aβ1-42 channels: Effects of solvent, pH, and Congo Red
27. Membrane perturbation by the neurotoxic Alzheimer amyloid fragment β25-35 requires aggregation and β-sheet formation
28. Prion fragment PrP[106-126] forms distinct channel types
29. Pore formation by the cytotoxic islet amyloid peptide amylin
30. Characterisation of a C-type natriuretic peptide CNP-39-formed cation-selective channel from platypus Ornithrorhynchus anatinus venom
31. Aggresomes and Russell bodies. Symptoms of cellular indigestion?
32. Amyloid-beta peptide assembly: A critical step in fibrillogenesis and membrane disruption
33. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by β-amyloid: Is NAC a common trigger or target in neurodegenerative disease?
34. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of prion peptide 106-126
35. Prion peptide fragment PrP[106-126] forms distinct cation channel types
36. Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide
37. Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta
38. Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro
39. Is polyproline II helix the killer conformation? A Raman optical activity study of the amyloidogenic prefibrillar intermediate of human lysozyme
40. Temperature-dependent beta-sheet formation in beta-amyloid Abeta(140) peptide in water: Uncoupling beta-structure folding from aggregation
41. The preaggregated state of an amyloidogenic protein: Hydrostatic pressure converts native transthyretin into the amyloidogenic state
42. Implications of macromolecular crowding for protein assembly
43. Protein aggregation and pathogenesis of Huntington's disease: Mechanisms and correlations
44. Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy
45. Simultaneous assessment of conformation and aggregation of beta-amyloid peptide using electrospray ionization mass spectrometry
46. Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles
47. Folding of beta-sheet membrane proteins: A hydrophobic hexapeptide model
48. Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides. Implications for drug development
49. Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions
50. PH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans
51. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide
52. Advanced glycation end products contribute to Amyloidosis in Alzheimer disease
53. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils
54. Manipulating the amyloid-beta aggregation pathway with chemical chaperones
55. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation
56. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synticlein in vitro
57. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors
58. Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc
59. Calcium-enhanced aggregation of serum amyloid P component and its inhibition by the ligands heparin and heparan sulphate. An electron microscopic and immunoelectrophoretic study
60. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro
61. Aluminium, beta-amyloid and non-enzymatic glycosylation
62. Identification of a penta-and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties
63. A biotechnological method provides access to aggregation competent monomeric Alzheimer's 1-42 residue amyloid peptide
64. Characterization of two highly amyloidogenic mutants of transthyretin
65. Stereochemical specificity of Alzheimer's disease beta-peptide assembly
66. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils
67. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei
68. Hsp70 and antifibrillogenic peptides promote degradation and inhibit intracellular aggregation of amyloidogenic light chains
69. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta
70. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E
71. Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein
72. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide
73. Alpha 1-antichymotrypsin interaction with A beta (1-42) does not inhibit fibril formation but attenuates the peptide toxicity
74. Alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity
75. Nicotine inhibits amyloid formation by the beta-peptide
76. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro
77. Anti-amyloidogenic activity of tetracycline: Studies in vitro
78. Inhibition of Huntington fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy
79. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide
80. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration
81. Protein engineering as a strategy to avoid formation of amyloid fibrils
82. Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: A general strategy to prevent amylold formation
83. Amyloid fibrillogenesis: Themes and variations